



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

REC'D 22 DEC 2004
WIPO PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

03027754.5

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

BEST AVAILABLE COPY



Anmeldung Nr:
Application no.: 03027754.5
Demande no:

Anmelddetag:
Date of filing: 02.12.03
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim
ALLEMAGNE
F. HOFFMANN-LA ROCHE AG
124 Grenzacherstrasse
4070 Basel
SUISSE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

Improved method for bisulfite treatment

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C07H/

Am Anmelddetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT RO SE SI SK TR LI

Improved method for bisulfite treatment

EPO - Mu
33
02 Dez. 20

Field of the invention

5 The invention is related to the detection of methylations in a nucleic acid wherein guanidinium hydrogen sulfite is used for the preparation of solutions containing guanidinium ions and sulfite ions and subsequent modification of the nucleic acid. Thereby, non-methylated cytosines are converted to uracil. The invention further discloses uses of guanidinium hydrogen sulfite and kits containing it.

Background of the invention

10 Genes constitute only a small proportion of the total mammalian genome, and the precise control of their expression in the presence of an overwhelming background of noncoding desoxyribonucleic acid (DNA) presents a substantial problem for their regulation. Noncoding DNA, containing introns, repetitive elements, and potentially active transposable elements requires effective mechanisms for its long 15 term silencing. Mammals appear to have taken advantage of the possibilities afforded by cytosine methylation to provide a heritable mechanism for altering DNA-protein interactions to assist in such silencing. DNA methylation is essential for the development of mammals; and plays a potential role during aging and cancer. The involvement of methylation in the regulation of gene expression and as 20 an epigenetic modification marking imprinted genes is well established. In mammals, methylation occurs only at cytosine residues and more specifically only on cytosine residues adjacent to a guanosine residue, i.e. at the sequence CG. The detection and mapping of DNA methylation sites are essential steps towards understanding the molecular signals which indicate whether a given sequence is 25 methylated.

This is currently accomplished by the so-called bisulfite method described by Frommer, M., et al., Proc. Natl. Acad. Sci. USA 89 (1992) 1827-1831) for the detection of 5-methyl-cytosines. The bisulfite method of mapping 5-methylcytosine uses the effect that sodium hydrogen sulfite reacts with cytosine but not or only 30 poorly with 5-methyl-cytosine. Cytosine reacts with bisulfite to form a sulfonated cytosine reaction intermediate being prone to deamination resulting in a sulfonated uracil which can be desulfonated to uracil under alkaline conditions. It is common

knowledge that uracil has the base pairing behavior of thymine different to the educt cytosine whereas 5-methylcytosine has the base pairing behavior of cytosine. This makes the discrimination of methylated or non-methylated cytosines possible by e.g. bisulfite genomic sequencing (Grigg, G., and Clark, S., Bioessays 16 (1994) 5 431-436; Grigg, G.W., DNA Seq. 6 (1996) 189-198) or methylation specific PCR (MSP) disclosed in US 5,786,146.

There are various documents addressing specific aspects of the bisulfite reaction (Benyajati, C., et al., Nucleic Acids Res. 8 (1980) 5649-5667) make general investigations to the bisulfite modification of 5-methyl-deoxycytosine and 10 deoxycytosine (Olek, A., et al., Nucleic Acids Res. 24 (1996) 5064-5066) disclose a method for bisulfite base sequencing whereby bisulfite treatment and subsequent PCR steps are performed on material embedded in agarose beads. In the bisulfite method as disclosed by Clark, S. J., et al., Nucleic Acids Res. 22 (1994) 2990-2997, the sample is desalted after deamination.

15 Raizis, A.M., et al., Anal. Biochem. 226 (1995) 161-166 disclose a bisulfite method of 5-methylcytosine mapping that minimizes template degradation. They investigate the influence of pH, temperature and time of reaction. Similar investigations have been made by Grunau, C., et al., Nucleic Acids Res. 29 (2001) E65-5 or Warnecke, P.M., et al., Methods 27 (2002) 101-107. Different additional 20 components in the bisulfite mixture are disclosed by WO 01/98528 or by Paulin, R., et al., Nucleic Acids Res. 26 (1998) 5009-5010. An additional bisulfite step after bisulfite treatment and PCR is disclosed in WO 02/31186. Komiya, M., and Oshima, S., Tetrahedron Letters 35 (1994) 8185-8188) investigate the catalysis of bisulfite-induced deamination of cytosine in oligodeoxyribonucleotides.

25 Kits for performing bisulfite treatments are commercially available from Intergen, distributed by Serologicals Corporation, Norcross, GA, USA, e.g. CpGenomeTM DNA modification kit.

A variation of the bisulfite genomic sequencing method is disclosed by Feil, R., et al., Nucleic Acids Res. 22 (1994) 695-696, whereby the genomic DNA is bound to 30 glass beads after deamination and washed. After elution the nucleic acid is desulfonated. It is known that nucleic acids can be isolated by the use of their binding behavior to glass surfaces, e.g. adsorption to silica gel or diatomic earths,

adsorption to magnetic glass particles (MGPs) or organo silane particles under chaotropic conditions. Extraction using solid phases usually contains the steps of adding the solution with the nucleic acids to the solid phase under conditions allowing binding of the substance of interest to the solid phase, removal of the

5 remainder of the solution from the solid phase bound nucleic acids and subsequent release of the nucleic acids from the solid phase into a liquid eluate (sometimes called elution). The result of the such process is usually a solution containing the substance of interest in dissolved state.

Guanidinium hydrogen sulfite is known from various documents. US 2,437,965

10 discloses a method for relaxing keratinous fibers using guanidinium hydrogen sulfite. US 2,654,678 discloses the antistatic treatment of shaped articles using guanidinium salts. US 4,246,285 discloses skin conditioning compositions containing guanidine inorganic salts. DE19527313 discloses guanidine derivatives and cosmetic articles containing them.

15 All prior art methods for the bisulfite treatment have disadvantages. Therefore, the problem to be solved by the present invention was to provide a method wherein guanidinium hydrogen sulfite is used.

Summary of the invention

20 The invention is related to a method for the conversion of a cytosine base in a nucleic acid to an uracil base comprising the steps of

a) providing a solution that contains a nucleic acid,

b) providing guanidinium hydrogen sulfite and preparing a solution comprising guanidinium and sulfite ions,

c) mixing the solutions from step a) and b)

25 d) incubating the solution obtained in step c) containing the nucleic acid and guanidinium and sulfite ions whereby the nucleic acid is deaminated,

- e) incubating the deaminated nucleic acid under alkaline conditions whereby the deaminated nucleic acid is desulfonated,
- f) isolating the deaminated nucleic acid.

In a further embodiment of the invention, guanidinium hydrogen sulfite is used for

- 5 chemically modifying a nucleic acid, particularly in a method wherein a cytosine base in a nucleic acid is converted to an uracil base. In another embodiment of the invention, guanidinium hydrogen sulfite is used to prepare a solution comprising guanidinium and sulfite ions, particularly the solution is used for converting a cytosine base in a nucleic acid to an uracil base.
- 10 In another embodiment of the invention, a kit containing guanidinium hydrogen sulfite is provided and uses of the kit according to the invention for a reaction wherein a cytosine base in a nucleic acid is converted to an uracil base in the presence of bisulfite ions.

According to the invention the term a "bisulfite reaction", "bisulfite treatment" or "bisulfite method" shall mean a reaction for the conversion of a cytosine base, in particular cytosine bases, in a nucleic acid to an uracil base, or bases, preferably in the presence of bisulfite ions whereby preferably 5-methyl-cytosine bases are not significantly converted. This reaction for the detection of methylated cytosines is described in detail by Frommer et al., *supra* and Grigg and Clark, *supra*. The

- 20 bisulfite reaction contains a deamination step and a desulfonation step which can be conducted separately or simultaneously (see Figure 1; Grigg and Clark, *supra*). The statement that 5-methyl-cytosine bases are not significantly converted shall only take the fact into account that it cannot be excluded that a small percentage of 5-methyl-cytosine bases is converted to uracil although it is intended to convert
- 25 only and exclusively the (non-methylated) cytosine bases (Frommer et al., *supra*).

Detailed description of the invention

The invention is related to a method for the conversion of a cytosine base in a nucleic acid to an uracil base comprising the steps of

- a) providing a solution that contains a nucleic acid,

- b) providing guanidinium hydrogen sulfite and preparing a solution comprising guanidinium and sulfite ions,
 - c) mixing the solutions from step a) and b)
 - d) incubating the solution obtained in step c) containing the nucleic acid and guanidinium and sulfite ions whereby the nucleic acid is deaminated,
 - e) incubating the deaminated nucleic acid under alkaline conditions whereby the deaminated nucleic acid is desulfonated,
 - f) isolating the deaminated nucleic acid.

5

10 Guanidinium hydrogen sulfite is a salt and used in solid form, i.e. it should be primarily in dry form and not contain water although minor amounts of water, including crystal water may be present. Guanidinium hydrogen sulfite may be produced as described in the invention (see Example 1) or as described in US 2,437,965, US 2,654,678, US 4,246,285 or DE 19527313.

15 The preparation of the solution comprising guanidinium and sulfite ions is accomplished by methods known to the expert skilled in the art, particularly by combining water or a buffered solution and the guanidinium hydrogen sulfite and mechanically agitation by e.g. shaking, stirring, pipetting the solution up and down or any other suitable means known to the expert skilled in the art. As said above, the guanidinium hydrogen sulfite may also be dissolved in a buffered solution

20 which may be an aqueous buffer, may contain further substances as organic substances, salts and buffering constituents known to the expert in the field as phosphate, Tris, HEPES or other suitable buffers.

25 The expert skilled in the art knows how to perform the bisulfite reaction, e.g. by referring to Frommer et al., *supra* or Grigg and Clark, *supra* who disclose the principal parameters of the bisulfite reaction. From Grunau et al., *supra*, it is known to the expert in the field what variations of the bisulfite method are possible. The influence of incubation time and temperature on deamination efficiency and parameters affecting DNA degradation is disclosed. In summary, in the deamination step a buffer containing bisulfite ions and chaotropic agents and

optionally further reagents as an alcohol or stabilizers as hydroquinone are employed and the pH is in the acidic range. The concentration of bisulfite is between 0.1 to 6 M bisulfite, preferably 1 M to 5.5 M, the concentration of the chaotropic agent is between 1 to 8 M, whereby in general preferably guanidinium

5 salts are employed but guanidinium hydrogen sulfite according to the invention as described herein, the pH is in the acidic range, preferably between 4.5 to 6.5, the temperature is between 0 °C to 90 °C, preferably between room temperature (25 °C) to 90 °C, and the reaction time is between 30 min to 24 hours or 48 hours or even longer, but preferably between 1 hour to 24 hours. The desulfonation step is

10 performed by adding an alkaline solution or buffer as e.g. a solution only containing a hydroxide, e.g sodium hydroxide, or a solution containing ethanol, sodium chloride and sodium hydroxide (e.g. 38% EtOH, 100 mM NaCl, 200 mM NaOH) and incubating at room temperature or elevated temperatures for several min, preferably 5 min to 60 min.

15 Therefore, in an embodiment of the invention, in the method according to the invention, the concentration of guanidinium ions and sulfite ions is 0,1 to 8 M, preferably 2 to 8 M. In an embodiment of the invention, the pH of the solutions in step b) and c) of the method according to the invention is in the acidic range, preferably between 4.5 to 6.5. In an embodiment of the method according to the

20 invention, the incubation temperature in step d) and e) of the method according to the invention is between 0 °C to 90 °C, preferably between 18 °C to 90 °C. In an embodiment of the method according to the invention, the incubation time in step d) is between 30 min to 48 hours, preferably 24 hours. In an embodiment of the invention, the step e) in the method according to the invention is performed by

25 adding an alkaline solution or buffer, preferably a solution containing a hydroxide, preferably sodium hydroxide, or a solution containing ethanol, sodium chloride and sodium hydroxide, preferably a solution containing 38% (volume/volume) ethanol, 100 mM NaCl, 200 mM NaOH. In an embodiment of the invention, in the method according to the invention, the incubation temperature in step e) is

30 between 0 °C to 90 °C, preferably between 18 °C to 90 °C. The incubation time in step e) of the method according to the invention is between 5 min to 60 min. In another embodiment of the invention, the incubation parameters as described in EP03001854.3 may be used, wherein the nucleic acid is incubated in a solution for a time period of 1.5 to 3.5 hours at a temperature between 70 and 90 °C, whereby the

35 concentration of bisulfite in the solution is between 3 M and 6.25 M and whereby

the pH value of the solution is between 5.0 and 6.0 whereby the nucleic acid is deaminated.

Desalting of the nucleic acid can be performed using magnetic glass particles as described in WO96/41811 or desulfonation and/ or desalting can be performed as

5 described in EP 02019097.1.

In an embodiment of the invention, the nucleic acid is desoxyribonucleic acid (DNA), in particular genomic DNA or nucleic acid, i.e. the DNA or nucleic acid which is found in the organism's genome and is passed on to offspring as information necessary for survival. The phrase is used to distinguish between other

10 types of DNA, such as found within plasmids. The source of the nucleic acid may be eukaryotic or prokarytic, preferably from vertebrates, particularly from mammals, most preferred from animals or humans.

In an embodiment of the invention the nucleic acid is obtained from a biological sample using e.g. solid phases (see e.g. WO96/41811 or WO01/37291 or the

15 MagNAPure® System available from Roche Diagnostics, Mannheim Germany) or other methods known to the expert in the field (see e.g. Sambrook et al.: Molecular Cloning, A Laboratory Manual, 2nd Addition, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY and Ausubel et al.: Current Protocols in Molecular Biology 1987, J. Wiley and Sons, NY or commercial DNA isolation kits available e.g.

20 from Qiagen, Hilden Germany). The biological sample comprises cells from multicellular organisms as e.g. human and animal cells such as Leucocytes, and immunologically active low and high molecular chemical compounds such as haptens, antigens, antibodies and nucleic acids, blood plasma, cerebral fluid, sputum, stool, biopsy specimens, bone marrow, oral rinses, blood serum, tissues,

25 urine or mixtures thereof. In a preferred embodiment of the invention the biological sample is a fluid from the human or animal body. The biological sample may be blood, blood plasma, blood serum or urine. The biological sample comprising the nucleic acid is lysed to create a mixture of biological compounds comprising nucleic acids and other components. Procedures for lysing biological

30 samples are known by the expert and can be chemical, enzymatic or physical in nature. A combination of these procedures is applicable as well. For instance, lysis can be performed using ultrasound, high pressure, shear forces, alkali, detergents or chaotropic saline solutions, or proteases or lipases. For the lysis procedure to obtain

nucleic acids, special reference is made to Sambrook et al.: Molecular Cloning, A Laboratory Manual, 2nd Addition, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY and Ausubel et al.: Current Protocols in Molecular Biology 1987, J. Wiley and Sons, NY. Then the nucleic acids are isolated from the lysis mixture using the methods and solid phases according to the invention and can then be subjected to the methods according to the invention, i.e. the bisulfite treatment according to the invention. Chaotropic agents are also used to lyse cells to prepare a mixture between nucleic acids and other biological substances (see e.g. Sambrook et al. (1989) or EP 0 389 063). Afterwards the material comprising glass or silica may be added and a purification effect results from the behavior of DNA or RNA to bind to material with a glass surface under these conditions i.e. in the presence of certain concentrations of a chaotropic agent, higher concentrations of organic solvents or under acidic conditions. Alternative methods may be used as well.

15 After the steps of the method according to the invention, further steps may be performed. In a preferred embodiment of the invention, the nucleic acid is amplified with the polymerase chain reaction (PCR; EP 0 201 184, EP-A-0 200 362, US 4,683,202). The amplification method may also be the ligase Chain Reaction (LCR, Wu, D.Y., and Wallace, R.B., Genomics 4 (1989) 560-569 and Barany, F., 20 Proc. Natl. Acad. Sci. USA 88 (1991) 189-193; Polymerase Ligase Chain Reaction (Barany, F., PCR Methods Appl. 1 (1991) 5-16); Gap-LCR (PCT Patent Publication No. WO 90/01069); Repair Chain Reaction (European Patent Publication No. EP 439,182 A2), 3SR (Kwoh, D.Y., et al., Proc. Natl. Acad. Sci. USA 86 (1989) 1173-1177; Guatelli, J.C., et al., Proc. Natl. Acad. Sci. USA 87 (1990) 1874-1878; PCT 25 Patent Publication No. WO 92/0880A), and NASBA (U.S. Pat. No. US 5,130,238). Further, there are strand displacement amplification (SDA), transcription mediated amplification (TMA), and Q β -amplification (for a review see e.g. Whelen, A.C., and Persing, D.H., Annu. Rev. Microbiol. 50 (1996) 349-373; Abramson, R.D., and Myers, T.W., Curr. Opin. Biotechnol. 4 (1993) 41-47). Particularly preferred 30 amplification methods according to the invention are the methylation specific PCR method (MSP) disclosed in US 5,786,146 which combines bisulfite treatment and allele-specific PCR (see e.g. US 5,137,806, US 5,595,890, US 5,639,611). The bisulfite treatment may be performed according to the invention.

In a preferred embodiment, the method may further comprise the step of detecting the amplified nucleic acid. The amplified nucleic acid may be determined or detected by standard analytical methods known to the person skilled in the art and described e.g. in Sambrook, et al., Molecular Cloning, Cold Spring Harbor

5 University Press (1989), Lottspeich and Zorbas, in "Bioanalytik" (1998), Eds. L. a. Zorbas, Spektrum Akademischer Verlag, Heidelberg, Berlin, Germany, or in Ausubel, F., et al., in "Current protocols in molecular biology" (1994), Eds. F. Ausubel, R. Brent and K. R.E., Wiley & Sons Verlag, New York. There may be also further purification steps before the target nucleic acid is detected e.g. a

10 precipitation step. The detection methods may include but are not limited to the binding or intercalating of specific dyes as ethidium bromide which intercalates into the double-stranded DNA and changes its fluorescence thereafter. The purified nucleic acids may also be separated by electrophoretic methods optionally after a restriction digest and visualized thereafter. There are also probe-based assays which

15 exploit the oligonucleotide hybridisation to specific sequences and subsequent detection of the hybrid. It is also possible to sequence the target nucleic acid after further steps known to the expert in the field. Other methods apply a diversity of nucleic acid sequences to a silicon chip to which specific probes are bound and yield a signal when a complementary sequences bind.

20 In a particularly preferred embodiment of the invention, the nucleic acid is detected by measuring the intensity of fluorescence light during amplification. This method entails the monitoring of real time fluorescence. A particularly preferred method exploiting simultaneous amplification and detection by measuring the intensity of fluorescent light is the TaqMan® method disclosed in WO 92/02638 and the

25 corresponding US patents US 5,210,015, US 5,804,375, US 5,487,972. This method exploits the exonuclease activity of a polymerase to generate a signal. In detail, the nucleic acid is detected by a process comprising contacting the sample with an oligonucleotide containing a sequence complementary to a region of the target nucleic acid and a labeled oligonucleotide containing a sequence complementary to

30 a second region of the same target nucleic acid strand, but not including the nucleic acid sequence defined by the first oligonucleotide, to create a mixture of duplexes during hybridization conditions, wherein the duplexes comprise the target nucleic acid annealed to the first oligonucleotide and to the labeled oligonucleotide such that the 3'-end of the first oligonucleotide is adjacent to the 5'-end of the labeled oligonucleotide. Then this mixture is treated with a template-dependent nucleic

35

acid polymerase having a 5' to 3' nuclease activity under conditions sufficient to permit the 5' to 3' nuclease activity of the polymerase to cleave the annealed, labeled oligonucleotide and release labeled fragments. The signal generated by the hydrolysis of the labeled oligonucleotide is detected and/ or measured. TaqMan®

5 technology eliminates the need for a solid phase bound reaction complex to be formed and made detectable. In more general terms, the amplification and/ or detection reaction of the method according to the invention is a homogeneous solution-phase assay. Further preferred method are the formats used in the LightCycler® instrument (see e.g. US 6,174,670). Particularly preferred is the use of

10 bisulfite treatment, amplification with or without methylation specific primers in the presence of a methylation-specific probe and real-time fluorescence detection as described in US 6,331,393.

In a preferred embodiment of the present invention, the method is automated, i.e. the method carries out an automatable process as e.g. described in WO 99/16781.

15 Automatable process means that the steps of the process are suitable to be carried out with an apparatus or machine capable of operating with little or no external control or influence by a human being. Automated method means that the steps of the automatable method are carried out with an apparatus or machine capable of operating with little or no external control or influence by a human being. Only the

20 preparation steps for the method may have to be done by hand, e.g. the storage containers have to filled up and put into place, the choice of the samples has to be done by a human being and further steps known to the expert in the field, e.g. the operation of the controlling computer. The apparatus or machine may e.g. add automatically liquids, mix the samples or carry out incubation steps at specific

25 temperatures. Typically, such a machine or apparatus is a robot controlled by a computer which carries out a program in which the single steps and commands are specified. In a preferred embodiment of the invention, the method is in a high-throughput format, i.e. the automated methods is carried out in a high-throughput format which means that the methods and the used machine or apparatus are

30 optimized for a high-throughput of samples in a short time.

Preferably the method according to the invention is used in diagnostics, for diagnostic analysis or for bioanalytics, or for the screening of tissue or fluids from the human or even animal body for the presence of certain methylation pattern.

Further, the method according to the invention is used to enhance the speed, accuracy or sensitivity of the detection of methylation sites in nucleic acids.

In an embodiment of the invention, guanidinium hydrogen sulfite is used for chemically modifying a nucleic acid, preferably wherein a cytosine base in a nucleic

5 acid is converted to an uracil base. In another embodiment of the invention, guanidinium hydrogen sulfite is used to prepare a solution comprising guanidinium and sulfite ions. Preferably, the solution is used for converting a cytosine base in a nucleic acid to an uracil base.

In another preferred embodiment, the present invention is directed to a kit for

10 performing a bisulfite reaction containing guanidinium hydrogen sulfite or a solution comprising bisulfite ions and guanidinium prepared from guanidinium hydrogen sulfite. Generally, kits known in the art further comprise plastics ware which may be used during the bisulfite procedure as e.g. microtiter-plates in the 96 or 384 well format or reaction tubes manufactured e.g. by Eppendorf, Hamburg,

15 Germany. Further, additional reagents may be present which contain buffers suitable for use in the present invention. Preferably, the kit according to the invention is used for a reaction wherein a cytosine base, preferably cytosine bases, in a nucleic acid is converted to an uracil base, preferably uracil bases, in the presence of bisulfite ions whereby preferably 5-methyl-cytosine bases are not significantly converted.

20 The following examples, references and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

25 **Description of the Figures**

Fig. 1: The steps of the bisulfite method

Fig. 2 to 4: HPLC profiles of the reaction mixtures after certain time periods as indicated in the examples

Fig. 2a) 1 M sodium hydrogensulfite, 30 min

30 Fig. 2b) 1 M guanidinium hydrogensulfite, 30 min

Fig. 3a) 2 M sodium hydrogensulfite, 30 min
Fig. 3b) 2M guanidinium hydrogensulfite, 30 min
Fig. 4a) 2 M sodium hydrogensulfite, 60 min
Fig. 4b) 2 M guanidinium hydrogensulfite, 60 min

5 Examples

1 Production of guanidinium hydrogen sulfite

130 g (722 mmol) of guanidine carbonate (Fluka 50930) was dissolved in 700 ml of water at room temperature. A stream of SO₂ was bubbled through this solution for several hours until pH 2-3 was measured. The yellow solution was lyophilised. The 10 yield of the colorless product was 184 g.

¹H-NMR ([D₆]DMSO, 300 MHz): δ = 7.12 (s, 6 H).

¹³C-NMR ([D₆]DMSO, 75 MHz): δ = 158.3.

Elementary analysis yielded data as expected

2 Desamination reaction with an oligonucleotide

15 2.1.1 Experimental design:

A double stranded nucleic acid formed from two oligonucleotides ("GSTP1 ds") is treated with sodium disulfite or guanidinium hydrogensulfite in different molar concentrations. After this procedure the GSTP1 ds is desulfonated and desalted. The purified GSTP1 ds is analysed by HPLC (see Fig. 2 to 4). The two 20 oligonucleotides forming the double-stranded nucleic acid ("GSTP1 ds") are described below and have the sequences SEQ ID NO: 1 and 2.

2.1.2 Method

2.1.2.1 Oligonucleotides

Oligo 1: 5'-GGG ACT CCA GGG CGC CCC TC-3' (SEQ ID NO: 1)

MW = 6079,97Da

5 1OD = 5,04nmol

Oligo 2: 5'-GAG GGG CGC CCT GGA GTC CC-3' (SEQ ID NO: 2)

MW = 6159,99Da

1OD = 4,83nmol

2.1.2.2 Deamination of GSTP1 ds using sodium disulfite:

10 5 nmol (MW 12239.96 Da) of GSTP1 ds are mixed with 200 μ l of bisulfite reagent (1-2M, pH 5.5) and incubated for several minutes (30 min - 60 min) at 80 °C.

2.1.2.3 Deamination of GSTP1 ds using guanidinium hydrogensulfite:

5 nmol (MW 12239.96 Da) of GSTP1 ds are mixed with 200 μ l of bisulfite reagent (1-2M, pH 5.5) and incubated for several minutes (30 min - 60 min) at 80 °C.

15 2.1.2.4 Desulfonation and desalting:

200 μ l of the deaminated GSTP1 ds are mixed with 500 μ l of 2N KOH and left for 30 minutes at room temperature. Thereafter a gel filtration with water on Sephadex G-25M (Pharmacia, Code No. 17-0851-01, Lot. No. QG 11018, bed volume 9ml) takes place. The solvent is removed and the residue dissolved in 200 μ l of water.

20 40 μ l are used for the HPLC.

2.1.2.5 HPLC:

Column: Dionex DNAPac PA-100SEL, 4x250mm

with precolumn: Product No. SP3816 Serial No. 0440

Solvent A: 0.2 M NaCl in 0.01 M NaOH

25 Solvent B: 1 M NaCl in 0.01 M NaOH

Gradient: 0 min : 50 % A/ 50 % B
25 min: 100 % B, 1 ml/min

The kinetic of the bisulfite reaction is analysed via HPLC. It is shown that under the same conditions the kinetic of the deamination process is much faster with relative 5 low concentrations (2 M) of guanidinium hydrogensulfite in comparison with the standard reagent sodiumhydrogensulfite (see Fig. 2 to 4). This shows clearly at relative low bisulfite concentration the advantages of the chaotropic guanidinium cation over sodium. The chromatogram of the 1 M bisulfite reaction is an example of the status shortly after starting the bulfite reaction. As later the elution the more 10 the deamination reaction is completed.

3 Establishment of a LC-PCR specific for Bisulphite treated DNA

3.1 General

The fact that the bisulfite reaction has worked and converted non-methylated cytosines to uracil can be demonstrated by a polymerase chain reaction whereby 15 primers are used which are specific to a region of the nucleic acid sequence wherein non-methylated cytosines have been converted to uracils, i.e. the base adenine in the primer is opposite to the uracil being the bisulfite reaction product from non-methylated cytosines. In case of incomplete conversion, the primer could not hybridize to this region as there would be cytosines not matching the adenine bases 20 in the primer. This would have the effect that no PCR product would be obtained.

An improved method to perform rapid polymerase chain reactions is disclosed e.g. in US 6,174,670 and is used in the LightCycler® instrument (Roche, Mannheim, Germany). In this method, two labeled probes can come into close proximity in an 25 amplificate dependent manner so that the two labels can perform a fluorescence energy transfer (FRET). The amount of the amplificate thereby correlates with the intensity of the emitted light of a certain wavelength. This specific PCR method can therefore be used to analyze whether a complete conversion of non-methylated cytosines was obtained, by e.g. analyzing the promoter region of the glutathion-S-transferase π gene (see e.g. SEQ ID NO: 3 for the full length sequence of this gene 30 and the promoter, US 5,552,277, Genbank accession code M24485 and Morrow, C.S., et al., Gene 75 (1989) 3-11) using suitable probes and primers. However, the expert skilled in the art knows that other methods can be used for this evaluation as

well. Fluorescence measurements are normalized by dividing by an initial fluorescence measurement, i.e., the background fluorescence, obtained during a cycle early in the reaction while the fluorescence measurements between cycles appear to be relatively constant. The cycle number chosen for the initial 5 fluorescence measurement is the same for all reactions compared, so that all measurements represent increases relative to the same reaction cycle. In the early cycles of a polymerase chain reaction amplification, the number of target molecules can be described by the geometric equation $N_i = N_0 \times (1 + E)^i$, where N_0 = the number of target molecules at the start of the reaction, N_i = the number of target 10 molecules at the completion of the i -th cycle, E = the efficiency of the amplification ($0 \leq E \leq 1$). During this geometric growth phase of the amplification, the number of cycles required to reach a particular threshold value (C_T value or crossing point) is inversely proportional to the logarithm of $(1 + E)$. Thus, the C_T 15 value represents a measure of the reaction efficiency that allows comparisons between reactions. A decrease in the C_T value, which means that the reaction reached the threshold value in fewer cycles, indicates an increase in reaction efficiency. As the increase in amplification product is monitored by measuring the increase in reaction fluorescence, the C_T is defined herein as the number of amplification cycles carried out until the fluorescence exceeded an arbitrary 20 fluorescence level (AFL). The AFL was chosen close to the baseline fluorescence level, but above the range of random fluctuations in the measured fluorescence, so that the reaction kinetics were measured during the geometric growth phase of the amplification. Accumulation of amplified product in later cycles inhibits the reaction and eventually leads to a reaction plateau. An AFL of 1.5 was chosen for all 25 reactions. Because a PCR amplification consists of discrete cycles and the fluorescence measurements are carried out once per cycle, the measured fluorescence typically increases from below the AFL to above the AFL in a single cycle. To improve the precision of the measurements, an "exact" number of cycles to reach the AFL threshold, referred to herein as the C_T value or crossing point, was 30 calculated by interpolating fluorescence measurements between cycles.

3.2 General methodology

The following experiment demonstrates that the described PCR on the LightCycler® instrument can be used as an evaluation tool for bisulfite treated DNA. It shows that the designed primer/probe combination gives positive results

only with DNA after bisulfite treatment. Bisulfite treated DNA (in this case bisulfite DNA was treated according to the protocol described in example 2) and untreated DNA were amplified in parallel using the same template concentrations (20ng and 1ng per PCR). PCR analysis on the LightCycler® instrument

5 3.2.1 Composition of Mastermix:

LC FastStart DNA Master HybridizationProbe 1x, 2mM MgCl₂, forward Primer 0.5μM, reversed Primer 0.5μM, donor probe 250nM, acceptor probe 250nM, template 10μl, total PCR volume 20μl.

3.2.2 PCR-conditions:

10 Denaturation 10min/95°C

55 cycles 95°C/10s

65°C/10s – signal acquisition

72°C/10s Ramp time 20°C/s

3.2.3 Result

MDNA / PCR	Bisulphite treatment	C _T -Value or Crossingpoint
20 ng	Yes	30.55 29.72 29.95 30.06
1 ng	yes	34.7 35.8 34.07 33.86
20 ng	No	No growth curve No growth curve No growth curve No growth curve
1 ng	No	No growth curve No growth curve

		No growth curve
		No growth curve

The result shows crossing points only for bisulfite treated DNA. Therefore this PCR is suitable in evaluating bisulfite methods. For those skilled in the art it is clear that any PCR might be used as an evaluation tool if it is guaranteed that the primer/probe combination does not react with DNA before bisulfite treatment.

5

4 Gua-Hydrogen- Sulfite can replace the standard deamination reagent Sodium-Bisulfite during analysis of DNA methylation

4.1 Experimental design:

Methylated DNA is spiked in unmethylated DNA, denatured and then treated in parallel with sodium bisulfite or guanidinium hydrogen sulfite. Therafter, the DNA is desalted using magnetic glass particles, desulfonated and again desalted. The purified DNA is analysed using a real time kinetic PCR protocol that detects only bisulfite treated methylated DNA.

10

4.1.1 Denaturation of DNA:

15 100 μ l of methylated DNA (Serologicals Corporation, Norcross, GA, USA; Cat S 7821) dilution (50 ng/assay spiked in 1000ng hDNA background, Roche Cat.1691112; 5 replicates per method), and 11 μ l 2 M NaOH are mixed and incubated for 10 min at 37 °C.

4.1.2 Deamination of DNA: Method 1 using standard reagent Sodium-Bisulfite

20 111 μ l of the denatured DNA are mixed with 200 μ l bisulfite reagent (2.5M sodium bisulfite =5M sulfite solution, 125 mM hydroquinone, pH 5.5) and incubated for 2 h at 80 °C.

4.1.3 Deamination of DNA: Method 2 using reagent Guanidinium-Hydrogen- Sulfite

111 µl of the denatured DNA are mixed with 200 µl bisulfite reagent (5M guanidinium hydrogen sulfite, pH 5.5) and incubated for 2 h at 80 °C.

5 4.1.4 Processing using MGPs

311 µl of the deaminated DNA are mixed with 600 µl binding buffer (MagNAPure DNA Isolation Kit I, Roche Cat. Nr. 3 003 990) and 75µl magnetic glass particle solution (MagNAPure DNA Isolation Kit I) and incubated for 15min/ room temperature with continuous mixing. Thereafter, the magnetic glass particles are

10 washed three times with 1ml 70% Ethanol. Bound free separation is done in a magnetic separator (Roche Cat.1641794). Thereafter, desulphonation takes place by adding 250 µl 90% EtOH / 20mM NaOH to the DNA bound to the MGPs; the mixture is incubated for 10min at room temperature with mixing. Thereafter the MGPs are washed two times with 90% Ethanol. To remove ethanol rests the MGPs

15 are heated for 15min./60°C in a thermomixer with open lid. Thereafter the DNA is eluted with 50µl 10mM Tris/0.1mM EDTA pH 7.5 (15min/ 60°C). 10µl of the eluted DNA is used for subsequent PCR analysis.

4.2 Analysis of deaminated DNA on the LightCycler® instrument

4.2.1 Composition of Mastermix

20 LightCycler® FastStart DNA Master HybridizationProbe 1x (Roche 2239272), 3mM MgCl₂, forward Primer 0.4 µM, reversed Primer 0.4 µM, donor probe 200 nM, acceptor probe 200 nM, template 10 µl, total PCR volume 20 µl.

4.2.2 PCR-conditions

Denaturation 10min/95°C

25 55 cycles 95°C/10s
 62°C/10s – signal acquisition
 72°C/10s Ramp time 20°C/s

4.3 Results:

replicates	Methylated DNA/PCR	Sodium bisulfite reagent	Guanidinium hydrogensulfite reagent
C_T -Values or Crossing points			
1	10ng	30.24	29.22
2	10ng	29.68	29.85
3	10ng	30.20	29.64
4	10ng	29.89	29.74
5	10ng	29.81	29.18
Mean value		29.96	29.53

The C_T -values or crossing points calculated during real time PCR are almost identical for both sulfite reagents used, for guanidinium hydrogensulfite the mean value is even lower; i.e. that guanidinium hydrogensulfite can replace the standard deamination reagent showing a somewhat better performance.

5 Use of guanidinium hydrogen sulfite without prior denaturation of DNA for methylation analysis

5.1 Experimental design:

10 Methylated DNA is spiked in unmethylated DNA, denatured or not denatured and then treated in parallel with sodium bisulfite or guanidinium hydrogen sulfite. Thereafter, the DNA is desalted using magnetic glass particles, desulphonated and again desalted. The purified DNA is analysed using a real time kinetic PCR protocol that detects only bisulfite treated methylated DNA.

15 5.1.1 Denaturation of DNA:

100 μ l of methylated DNA (Serologicals Corporation, Norcross, GA, USA; Cat S 7821) dilution (50 ng/assay spiked in 1000ng hDNA background, Roche Cat.1691112; 4 replicates per method), and 11 μ l 2 M NaOH are mixed and incubated for 10 min at 37 ° C.

5.1.2 Deamination of DNA: Method 1 using standard reagent Sodium-Bisulfite

111 µl of the denatured DNA or 100µl of not denatured DNA are mixed with 200 µl bisulfite reagent (2.5M sodium bisulfite, 125 mM hydroquinone, pH 5.5) and incubated for 2 h at 80 °C.

5 5.1.3 Deamination of DNA: Method 2 using reagent Guanidinium-Hydrogen-Sulfite

111 µl of the denatured DNA or 100µl of not denatured DNA are mixed with 200 µl bisulfite reagent (5M guanidinium hydrogen sulfite, pH 5.5) and incubated for 2 h at 80 °C.

10 5.1.4 Processing using MGPs

311 µl of the deaminated DNA are mixed with 600 µl binding buffer (MagNAPure DNA Isolation Kit I, Roche Cat. Nr. 3 003 990) and 75µl magnetic glass particle solution (MagNAPure DNA Isolation Kit I) and incubated for 15 min/ room temperature with continuous mixing. Thereafter, the magnetic glass particles are washed three times with 1ml 70% Ethanol. Bound free separation is done in a magnetic separator (Roche Cat.1641794). Thereafter, desulphonation takes place by adding 250 µl 90% EtOH / 20mM NaOH to the DNA bound to the MGPs; the mixture is incubated for 10min at room temperature with mixing. Thereafter the MGPs are washed two times with 90% Ethanol. To remove residual ethanol the MGPs are heated for 15min/60°C in a thermomixer with open lid. Thereafter the DNA is eluted with 50µl 10mM Tris/0.1mM EDTA pH 7.5 (15min./60°C). 10µl of the eluted DNA is used for subsequent PCR analysis.

5.2 Analysis of deaminated treated DNA on the LightCycler® instrument

5.2.1 Composition of Mastermix

25 LightCycler® FastStart DNA Master HybridizationProbe 1x (Roche 2239272), 3mM MgCl₂, forward Primer 0.4 µM, reversed Primer 0.4 µM, donor probe 200 nM, acceptor probe 200 nM, template 10 µl, total PCR volume 20 µl.

5.2.2 PCR-conditions

Denaturation 10min/95°C

55 cycles 95°C/10s

62°C/10s – signal acquisition

5 72°C/10s Ramp time 20°C/s

5.3 Results:

replicates	Methylated DNA/PCR	Sodium disulfite reagent With denaturation	Guanidinium hydrogensulfite reagent With denaturation	Sodium disulfite reagent Without denaturation	Guanidinium hydrogensulfite reagent Without denaturation
C_T -Values or Crossing points					
1	10ng	29.74	29.06	34.35	33.62
2	10ng	29.48	29.85	35.17	33.92
3	10ng	29.66	29.86	33.64	33.60
4	10ng	29.80	29.86	33.10	33.63
<i>Mean value</i>		29.67	29.66	34.07	33.69

The result shows that the Bisulfite reaction does work without prior denaturation of DNA; the novel reagent guanidinium hydrogen sulfite is more efficient because the median of the crossing points is lower than that of the standard bisulfite reagent.

10 6 Guanidinium Hydrogensulfite can be used in lower molar concentrations for methylation analysis

6.1 Experimental design:

Methylated DNA is spiked in unmethylated DNA, denatured and then treated in parallel with sodium disulfite or guanidinium hydrogen sulfite in different molar concentrations. Therafter, the DNA is desalted using magnetic glass particles, desulfonated and again desalted. The purified DNA is analysed using a real time kinetic PCR protocol that detects only bisulfite treated methylated DNA.

6.1.1 Denaturation of DNA:

100 μ l of methylated DNA (Serologicals Corporation, Norcross, GA, USA; Cat S 7821) dilution (50 ng/assay spiked in 1000ng hDNA background, Roche Cat.1691112; 4 replicates per method), and 11 μ l 2 M NaOH are mixed and
5 incubated for 10 min at 37 °C.

6.1.2 Deamination of DNA: Method 1 using standard reagent Sodium-Bisulfite

111 μ l of the denatured DNA or 100 μ l of not denatured DNA are mixed with 200 μ l bisulfite reagent (2.5M – 1.5M – 0.5M sodium disulfite, 125 mM hydroquinone, pH 5.5) and incubated for 2 h at 80 °C. (Comment: a 2.5M solution of sodium
10 disulfite is 5M regarding sulfite ions)

6.1.3 Deamination of DNA: Method 2 using reagent Guanidinium-Hydrogen-Sulfite

111 μ l of the denatured DNA or 100 μ l of not denatured DNA are mixed with 200 μ l bisulfite reagent (5M – 3M – 1M guanidinium hydrogen sulfite, pH 5.5) and
15 incubated for 2 h at 80 °C.

6.1.4 Processing using MGPs

311 μ l of the deaminated DNA are mixed with 600 μ l binding buffer (MagNAPure DNA Isolation Kit I, Roche Cat. Nr. 3 003 990) and 75 μ l magnetic glass particle solution (MagNAPure DNA Isolation Kit I) and incubated for 15min/ room
20 temperature with continuous mixing. Thereafter, the magnetic glass particles are washed three times with 1ml 70% Ethanol. Bound free separation is done in a magnetic separator (Roche Cat.1641794). Thereafter, desulphonation takes place by adding 250 μ l 90% EtOH / 20mM NaOH to the DNA bound to the MGPs; the mixture is incubated for 10min at room temperature with mixing. Thereafter the
25 MGPs are washed two times with 90% Ethanol. To get rid of ethanol rests the MGPs were heated for 15min./60°C in a thermomixer with open lid. Thereafter the DNA is eluted with 50 μ l 10mM Tris/0.1mM EDTA pH 7.5 (15min./60°C). 10 μ l of the eluted DNA is used for subsequent PCR analysis.

6.2 Analysis of deaminated treated DNA on the LightCycler® instrument

6.2.1 Composition of Mastermix

LightCycler® FastStart DNA Master HybridizationProbe 1x (Roche 2239272),

3mM MgCl₂, forward Primer 0.4 μM, reversed Primer 0.4 μM, donor probe 200

5 nM, acceptor probe 200 nM, template 10 μl, total PCR volume 20 μl.

6.2.2 PCR-conditions

Denaturation 10min/95°C

55 cycles 95°C/10s

62°C/10s – signal acquisition

10 72°C/10s Ramp time 20°C/s

6.3 Results:

Replicates	Methylated DNA/PCR	Amount of sulfite during deamination reaction	Sodium reagent	disulfite	Guanidinium hydrogensulfite reagent
					C _T -Values or Crossing points
1	10ng	5M	29.24		28.56
2	10ng	5M	29.36		29.35
3	10ng	5M	29.19		28.87
4	10ng	5M	29.61		28.94
<i>Mean value</i>			29.35		28.93
1	10ng	3M	30.67		29.76
2	10ng	3M	30.20		29.68
3	10ng	3M	30.61		30.59
	10ng	3M	31.10		30.53
<i>Mean value</i>			30.65		30.14
1	10ng	1M	-		-
2	10ng	1M	-		-
3	10ng	1M	-		-
4	10ng	1M	41.64		-
<i>Mean value</i>					

The results show that desamination is also possible with a lower molar concentration of sulfite ions, but the sensitivity drops; a concentration of 1M is too low. The novel reagent is somewhat more efficient because the difference in crossing points between 5M and 3M is 1.21, whereas for the standard reagent it is

5 1.3.

7 GuaSulfit can be used for solid phase deamination in DNA methylation analysis

7.1 Experimental design

Methylated DNA is spiked in unmethylated DNA, denatured in solution and 10 transfer to silica solid phase (column). Deamination is done in parallel with sodium disulfite or guanidinium hydrogen sulfite. Thereafter the DNA is desalting, desulfonated and again desalting. The purified DNA is analysed using a real time kinetic PCR protocol that detects only bisulfite treated methylated DNA.

7.1.1 Denaturation of DNA:

15 100 µl of methylated DNA (Serologicals Corporation, Norcross, GA, USA; Cat S 7821) dilution (50 ng/assay spiked in 1000ng hDNA background, Roche Cat.1691112; 3 replicates per method), and 11 µl 2 M NaOH are mixed and incubated for 15 min at 37 °C.

7.1.2 Solid Phase Deamination of DNA: Method 1 using standard reagent

20 Sodium-Bisulfite

111 µl of the denatured DNA are mixed with 300 µl bisulfite reagent (2,5M sodium bisulfite = 5M sulfite in solution, pH 5.5) and 100µl ethanol and loaded on to a silica column (from High Pure Template Preparation Kit, Roche, 1796828); incubation is overnight at 50°C.

7.1.3 Solid Phase Deamination of DNA: Method 2 using reagent Guanidinium-Hydrogen- Sulfite

111 μ l of the denatured DNA are mixed with 300 μ l bisulfite reagent (5M guanidinium hydrogensulfite, pH 5.5) and 100 μ l ethanol and loaded on to a silica column (from High Pure Template Preparation Kit, Roche, 1796828); incubation is overnight at 50°C.

5

7.1.4 Processing on silica columns

After overnight incubation columns are centrifuged 1min/8000rpm (Eppendorf bench top centrifuge) and two times washed with 500 μ l 70% ethanol.

10 Desulfonation is performed by adding 500 μ l reagent (38% ethanol/100mM EDTA/200mM NaOH) and incubation for 20min. at room temperature. After short centrifugation the columns are washed twice with 500 μ l 90% ethanol each. To remove the entire ethanol the columns are centrifuged for 20sec at 14000rpm. Bound DNA is eluted by adding 100 μ l prewarmed (70°C) PCR grade water. The columns are centrifuged again and the supernatant is used for subsequent PCR analysis.

15

7.2 Analysis of deaminated treated DNA on the LightCycler® instrument

7.2.1 Composition of Mastermix

LightCycler® FastStart DNA Master HybridizationProbe 1x (Roche 2239272),

20 3mM MgCl₂, forward Primer 0.4 μ M, reversed Primer 0.4 μ M, donor probe 200 nM, acceptor probe 200 nM, template 10 μ l, total PCR volume 20 μ l.

7.2.2 PCR-conditions

Denaturation 10min/95°C

55 cycles 95°C/10s

25 62°C/10s – signal acquisition

72°C/10s Ramp time 20°C/s

7.3 Results:

Replicates	Solid phase desamination with Sodium disulfite reagent	Solid phase desamination with Guanidinium hydrogensulfite reagent
C_T-Values or Crossing points		
1	32.72	31.68
2	32.85	31.64
3	32.47	31.75
Mean value	32.68	31.69

The results show that solid phase desamination is possible with both sulfite reagents, but the efficiency for the novel reagent is significantly higher: the resulting 5 crossing points are 1 cycle earlier corresponding to a twofold better yield of bisulfite treated DNA.

8 GuaSulfit can be used for combined process SP + BIS

8.1 Experimental design

A clinical sample is directly contacted with the bisulfite reagent (GuaSulfit or Na-10 Bisulfit) without prior purification of the DNA. After incubation the processing of the converted DNA is done using the magnetic glass particles as usual. The purified DNA is analysed using a real time kinetic PCR protocol that detects only bisulfite treated DNA.

8.1.1 Combined SP and BIS process:

15 200 μ l of normal human serum or normal human serum spiked with 0.2 μ g of nucleosomal DNA (3 replicates each) are mixed with 50 μ l Proteinase K (Roche) and 600 μ l BIS reagent (either 6M Guanidiniumhydrogen -Sulfit or 5M Sodiumbisulfite); pH is adjusted to 5.5 with 5M NaOH. Then the mixture is incubated for 2h at 80°C in a thermomixer.

8.1.2 Processing using MGPs

Thereafter 6mg magnetic glass particles ((MagNAPure DNA Isolation Kit I, Roche Cat. Nr. 3 003 990) in 600 μ l isopropanol are added, and the solution is mixed thoroughly and incubated for 15min/ room temperature with continuous mixing.

- 5 Thereafter, the magnetic glass particles are washed three times with 1ml 70% Ethanol. Bound free separation is done in a magnetic separator (Roche Cat.1641794). Thereafter, desulphonation takes place by adding 250 μ l 90% EtOH / 20mM NaOH to the DNA bound to the MGPs; the mixture is incubated for 10min at room temperature with mixing. Thereafter the MGPs are washed two times with
- 10 90% Ethanol. To get rid of ethanol rests the MGPs were heated for 15min./60°C in a thermomixer with open lid. Thereafter the DNA is eluted with 50 μ l 10mM Tris/0.1mM EDTA pH 7.5 (15min./60°C). 10 μ l of the eluted DNA is used for subsequent PCR analysis.

8.2 Analysis of deaminated treated DNA on the LightCycler® instrument

15 8.2.1 Composition of Mastermix

LightCycler® FastStart DNA Master HybridizationProbe 1x (Roche 2239272), 2mM MgCl₂, forward Primer 0.5 μ M, reversed Primer 0.5 μ M, donor probe 300 nM, acceptor probe 300 nM, template 10 μ l, total PCR volume 20 μ l.

8.2.2 PCR-conditions

20 Denaturation 10min/95°C

55 cycles 95°C/10s

62°C/10s – signal acquisition

72°C/10s Ramp time 20°C/s

8.3 Results:

Sample	Sodium disulfite reagent	Guanidinium hydrogensulfite reagent
C_T -Values or Crossing points		
NS	No growth curve	43.04

NS	No growth curve	37.67
NS	No growth curve	40.96
<i>Mean value</i>	-	40.56
NS + DNA	36.75	35.37
NS + DNA	37.56	34.40
NS + DNA	37.55	36.26
<i>Mean value</i>	37.29	35.34

The results show that the new format "combination of Sample preparation and BIS-Treatment" results in converted, amplifiable DNA. For the standard BIS reagent positive results are seen only for the spiked samples; that means that the

5 overall efficiency of the process is still quite limited. In contrast however using the novel BIS reagent results in positive results for the unspiked serum as well as the spiked serum, indicating that the novel BIS reagent can be used more efficiently for the combined SP-BIS format than the standard reagent.

9 GuaSulfit can be used as Binding reagent for DNA isolation on silica surfaces

10 9.1 Experimental design

50ng human genomic DNA, Roche 1691112 is spiked in 200 μ l normal negative serum. Then the DNA is isolated using the High Pure Template preparation kit (Roche 1796828) either with the recommended binding buffer or with 5M Guanidinium hydrogensulfit pH 5.5 or 5M Sodium Bisulfite pH 5.5 as binding
15 buffer (3 replicates each). The purified DNA is then quantified in a real time kinetic PCR using the LC Control Kit (Roche 2015102) that detects β Globin DNA.

9.2 Results

Replicates	Original Binding Buffer	5M Sodium Bisulfite as	5M Guanidinium Hydrogensulfite as

			Binding buffer		Binding buffer	
	cp	ng DNA	cp	ng DNA	cp	ng DNA
1	26.6	50.2	28.97	9.56	29.61	6.11
2	26.59	50.4	28.72	11.4	29.36	7.32
3	26.74	45.6	28.95	9.74	29.56	6.34
Mean value	26.64	48.7	28.88	10.2	29.51	6.6

The results show that the original binding buffer in the kit gives the best performance, but both sulfite reagents might be used also as binding buffers; the novel reagent is somewhat less efficient and some more optimization might be needed.

List of References

Abramson, R.D., and Myers, T.W., *Curr. Opin. Biotechnol.* 4 (1993) 41-47

Alderton, R.P., et al., *Anal. Biochem.* 201 (1992) 166-169

Ausubel, F., et al., in "Current protocols in molecular biology" (1994), Eds. F.

5 Ausubel, R. Brent and K. R.E., Wiley & Sons Verlag, New York

Barany, F., *PCR Methods Appl.* 1 (1991) 5-16

Barany, F., *Proc. Natl. Acad. Sci. USA* 88 (1991) 189-193

Benyajati, C., et al., *Nucleic Acids Res.* 8 (1980) 5649-5667

Braunauer, in "The Adsorption of Gases and Vapors" (1943), Princeton University

10 Press

Clark, S.J., et al., *Nucleic Acids Res.* 22 (1994) 2990-2997

DE 3724442

EP 0 200 362

EP 0 201 184

15 EP 0 389 063

EP 0 439 182

Feil, R., et al., *Nucleic Acids Res.* 22 (1994) 695-696

Frommer, M., et al., *Proc. Natl. Acad. Sci. U S A* 89 (1992) 1827-1831

GB 91/00212

20 Grigg, G., and Clark, S., *Bioessays* 16 (1994) 431-436

Grigg, G.W., *DNA Seq.* 6 (1996) 189-198

Grunau, C., et al., *Nucleic Acids Res.* 29 (2001) E65-5

Guatelli, J.C., et al., *Proc. Natl. Acad. Sci. USA* 87 (1990) 1874-1878

Jakobi, R., et al., *Anal. Biochem.* 175 (1988) 196-201

25 Komiyama, M., and Oshima, S., *Tetrahedron Letters* 35 (1994) 8185-8188

Kwoh, D.Y., et al., *Proc. Natl. Acad. Sci. USA* 86 (1989) 1173-1177

Lottspeich, and Zorbas, in "Bioanalytik" (1998), Eds. L. a. Zorbas, Spektrum

Akademischer Verlag, Heidelberg, Berlin, Germany

Marko, M.A., et al., *Anal. Biochem.* 121 (1982) 382-387

30 Morrow, C.S., et al., *Gene* 75 (1989) 3-11

Oakeley, E.J., *Pharmacol. Ther.* 84 (1999) 389-400

Olek, A., et al., *Nucleic Acids Res.* 24 (1996) 5064-5066


Paulin, R., et al., *Nucleic Acids Res.* 26 (1998) 5009-5010

Raizis, A.M., et al., *Anal. Biochem.* 226 (1995) 161-166

Sambrook, J., et al., in "Molecular Cloning: A Laboratory Manual" (1989), Eds. J. Sambrook, E. F. Fritsch and T. Maniatis, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY

Spray Drying Handbook (1991), John Wiley & Sons, New York

- 5 US 4,683,202
- US 5,130,238
- US 5,137,806
- US 5,210,015
- US 5,234,809
- 10 US 5,487,972
- US 5,552,277
- US 5,595,890
- US 5,639,611
- US 5,786,146
- 15 US 5,804,375
- US 6,174,670
- US 6,331,393
- Vogelstein, B., and Gillespie, D., Proc. Natl. Acad. Sci. USA 76 (1979) 615-619
- Warnecke, P.M., et al., Methods 27 (2002) 101-107
- 20 Whelen, A.C., and Persing, D.H., Annu. Rev. Microbiol. 50 (1996) 349-373
- WO 00/32762
- WO 00/37291
- WO 01/37291
- WO 01/98528
- 25 WO 02/31186
- WO 90/01069
- WO 90/06045
- WO 92/02638
- WO 92/0880A
- 30 WO 96/41811
- WO 99/16781
- WO 99/40098
- Wu, D.Y., and Wallace, R.B., Genomics 4 (1989) 560-569



EPO - Munich
33
02 Dez. 2003

Patent Claims

1. Method for the conversion of a cytosine base in a nucleic acid to an uracil base comprising the steps of
 - g) providing a solution that contains a nucleic acid,
 - 5 h) providing guanidinium hydrogen sulfite and preparing a solution comprising guanidinium and sulfite ions,
 - i) mixing the solutions from step a) and b)
 - j) incubating the solution obtained in step c) containing the nucleic acid and guanidinium and sulfite ions whereby the nucleic acid is deaminated,
 - 10 k) incubating the deaminated nucleic acid under alkaline conditions whereby the deaminated nucleic acid is desulfonated,
 - l) isolating the deaminated nucleic acid.
2. The method according to claim 1 characterized in that
 - 15 the concentration of guanidinium ions and sulfite ions is 0,1 to 8 M, preferably 2 to 8 M.
3. The method according to any of the claims 1 to 2 characterized in that
 - 20 the pH of the solutions in step b) and c) is in the acidic range, preferably between 4.5 to 6.5
4. The method according to any of the claims 1 to 3 characterized in that
 - the incubation temperature in step d) and e) is between 0 °C to 90 °C, preferably between 18 °C to 90 °C.

5. The method according to any of the claims 1 to 4 characterized in that the incubation time in step d) is between 30 min to 48 hours, preferably 24 hours.
- 5 6. The method according to any of the claims 1 to 5 characterized in that the step e) is performed by adding an alkaline solution or buffer, preferably a solution containing a hydroxide, preferably sodium hydroxide, or a solution containing ethanol, sodium chloride and sodium hydroxide, 10 preferably a solution containing 38% (volume/volume) ethanol, 100 mM NaCl, 200 mM NaOH.
- 15 7. The method according to any of the claims 1 to 6 characterized in that the incubation temperature in step e) is between 0 °C to 90 °C, preferably between 18 °C to 90 °C.
8. The method according to any of the claims 1 to 7 characterized in that the incubation time in step e) is between 5 min to 60 min.
- 20 9. Use of guanidinium hydrogen sulfite for chemically modifying a nucleic acid.
10. Use according to claim 9 wherein a cytosine base in a nucleic acid is converted to an uracil base.
11. Use of guanidinium hydrogen sulfite to prepare a solution comprising guanidinium and sulfite ions.
- 25 12. Use according to claim 1 wherein the solution is used for converting a cytosine base in a nucleic acid to an uracil base.
13. A kit containing guanidinium hydrogen sulfite.

14. Use of the kit according to claim 13 for a reaction wherein a cytosine base in a nucleic acid is converted to an uracil base in the presence of bisulfite ions.

Abstract

02 Dez. 2003

The invention is related to the detection of methylations in a nucleic acid wherein guanidinium hydrogen sulfite is used for the preparation of solutions containing guanidinium ions and sulfite ions and subsequent modification of the nucleic acid.

5 Thereby, non-methylated cytosines are converted to uracil. The invention further discloses uses of guanidinium hydrogen sulfite and kits containing it.

SEQUENCE LISTING

EPO - Munich
33
02 Dez. 2003

<110> Roche Diagnostics GmbH
F. Hoffmann-La Roche AG

<120> Improved method for bisulfite treatment

<130> 22307 EP

<160> 3

<170> PatentIn version 3.2

<210> 1
<211> 20
<212> DNA
<213> Homo sapiens

<400> 1
gggactccag ggcgcccctc
20

<210> 2
<211> 20
<212> DNA
<213> Homo sapiens

<400> 2
gagggggcgcc ctggagtccc
20

<210> 3
<211> 4261
<212> DNA
<213> Homo sapiens

<300>
<301> Morrow et al.
<302> Structure of the human genomic glutathion S-transferase pi gene
<303> Genes and Development
<304> 75
<306> 3-11
<307> 1989-01-01

<300>
<308> M24485
<309> 2000-03-04
<313> (1)..(4261)

<300>
<302> Genetic Diagnosis of Prostate cancer
<310> US5,552,277
<311> 1994-07-19
<312> 1996-09-03

<313> (1) .. (4261)

<220>
<221> misc_signal
<222> (1156) .. (1162)
<223> transcription regulatory motif; putative

<220>
<221> GC_signal
<222> (1169) .. (1174)

<220>
<221> GC_signal
<222> (1179) .. (1184)

<220>
<221> GC_signal
<222> (1194) .. (1198)

<220>
<221> GC_signal
<222> (1225) .. (1254)

<220>
<221> GC_signal
<222> (4041) .. (4046)

<400> 3
aacaagagat caatatctag aataaatgga gatctgcaaa tcaacagaaa gtaggca^gca
60
aagccaaaga aaatagccta aggcacagcc actaaaagga acgtgatcat gtccttgca
120
gggacatggg tggagctgga agccgttagc ctcagcaa^{ac} tcacacagga acagaaaacc
180
agcgagacccg catggctctca cttataagt^g ggagctgaac aatgagaaca catggtcaca
240
tggcggcgat caacacacac tggtgctgt tgagcggggt gctggggagg gagagtacca
300
ggaagaatag ctaaggata ctgggcttaa tacctgggtg atggatgat ctgtacagca
360
aaccatcatg ggcacacac c^tatgtaaca aac^tgcaca tcctgcacat gtacccaga
420
acttcaaata aaagttggac ggccaggcgt ggtggctcac gcctgtaatc ccagcacttt
480
ggaaagccga ggcgtgcaga tcacctaagg tcaggagttc gagaccagcc cggccaacat
540

ggtaaaaccc cgtctact aaaaatacaa aaatcagcca gatgtggcac gcacctataa
600
ttccacctac tcggaggct gaagcagaat tgcttgaacc cgagaggcgg aggttgcagt
660
gagccgcccga gatcgccca ctgcactcca gcctggcca cagcgtgaga ctacgtcata
720
aaataaaata aaataacaca aaataaaata aaataaaata aaataaaata aaataataaa
780
ataaaataaa ataaaataaa ataaaataaa ataaagcaat ttccttcct ctaagcggcc
840
tccacccctc tcccctgccc tgtgaagcgg gtgtgcaagc tccggatcg cagcggctt
900
agggatattc ccccgcgat gtcccgccgc gccagttcgc tgccacact tcgctgcgg
960
cctttcctg ctgtctgtt actccctagg ccccgctggg gacctgggaa agagggaaag
1020
gctccccgg ccagctgcgc ggcgactccg gggactccag ggcgcctc tgcggccgac
1080
gcccggggtg cagcgccgc cgggctggg gccggcggga gtccgcggga ccctccagaa
1140
gagcggccgg cgccgtact cagcactggg gcggagcggg gcgggaccac cttataagg
1200
ctcggaggcc gcgaggcctt cgctggagtt tcgcccgc agtttcgcc accagttagt
1260
acgcgcggcc cgctccccgg ggatggggct cagagctccc agcatggggc caacccgcag
1320
catcaggccc gggctccccgg cagggctcct cgcccaccc gagacccggg acggggccct
1380
aggggaccca ggacgtcccc agtgccgtta gcggcttca gggggcccg agcgccctcg
1440
ggagggatgg gacccgggg gcggggaggg gggcaggct gcgcacccg cgcctggca
1500
tcctcccccg ggctccagca aactttctt tgttcgctgc agtgcgcacc tacaccgtgg
1560
tctatttccc agtcgaggt aggagcatgt gtctggcagg gaaggagggc agggctggg
1620
gctgcagccc acagccctc gcccacccgg agagatccga acccccttat ccctccgtcg
1680

tgtggctttt accccgggccc tccttcatgt tccccgcctc tcccgccatg cctgctcccc
1740

gccccagtgt tgtgtgaaat ctccggagga acctgtttac ctgttccctc cctgcactcc
1800

tgacccctcc ccgggttgct gcgaggcgg a tccggcccg tccccacatc tcgtacttct
1860

ccctccccgc aggccgctgc gcggccctgc gcatgctgct ggcagatcag ggccagagct
1920

ggaaggagga ggtgggtgacc gtggagacgt ggcaggaggg ctcactcaaa gcctcctgcg
1980

taagtgacca tgcccgccca aggggagggg gtgctggcc ttagggggct gtgacttagga
2040

tcgggggacg cccaaagctca gtgcccctcc ctgagccatg cctccccaa cagctatacg
2100

ggcagctccc caagttccag gacggagacc tcaccctgta ccagtccaaat accatcctgc
2160

gtcacctggg ccgcaccctt ggtgagtc tt gacccctt gacccctt gtcaggggca ggcattggca
2220

agcctctgcc cccggagccc ttttggtaa atcagctgcc ccgcagccct ctggagtgga
2280

gaaaactgag acccactgag gttacgtgt ttgccaagg tcaagcctgg gtgcctgcaa
2340

tccttgcctt gtgccaggct gcctccagg tgcaggta gctctgagca cctgctgtgt
2400

ggcagtcctt catccttcca cgcacatcct cttccctcc tcccaggctg gggctcacag
2460

acagccccct ggttggccca tccccagtga ctgtgtgtt atcaggcgcc cagtcacgcg
2520

gcctgctccc ctccacccaa ccccaggct ctatggaaag gaccagcagg aggcagccct
2580

ggtgacatg gtgaatgacg gcgtggagga cttccgctgc aaatacatct ccctcatcta
2640

caccaactat gtgagcatct gcaccagggt tgggcactgg gggctgaaca aagaaagggg
2700

cttcttgc ctcacccccc cttacccctc aggtggcttg ggctgacccc ttcttggtc
2760

agggtgcagg ggctgggtca gctctgggcc aggggcccag gggcctggga caagacacaa
2820

cctgcaccct tattgcctgg gacatcaacc agccaagtaa cgggtcatgg gggcgagtgc
2880

aaggacagag acctccagca actggtggtt tctgatctcc tgggtggcg agggttcct
2940

ggagtagcca gaggtggagg aggatttgc gccagttct ggatggaggt gctggcactt
3000

ttagctgagg aaaatatgca gacacagagc acatttgggg acctgggacc agttcagcag
3060

aggcagcgtg tgtgcgcgtg cgtgtgcgtg tgtgtgcgtg tgtgtgtgt a cgcttgcatt
3120

tgtgtcgggt gggtaaggag atagagatgg gcgggcagta ggcccaggc ccgaaggcct
3180

tgaacccact ggtttggagt ctcctaaggg caatggggc cattgagaag tctgaacagg
3240

gctgtgtctg aatgtgaggt ctagaaggat cttccagaga agccagctct aaagctttt
3300

caatcatctg gtgagagaac ccagcaagga tggacaggca gaatgaaata gagatgagtt
3360

ggcagctgaa gtggacagga ttttgtacta gcctgggtgt ggggagcaag cagaggagaa
3420

tctggactc tgggtctgg cctggggcag acgggggtgt ctcagggct gggaggatg
3480

agagtaggat gatacatggt ggtgtctggc aggaggcggg caaggatgac tatgtgaagg
3540

cactgcccgg gcaactgaag cttttgaga ccctgctgtc ccagaaccag ggaggcaaga
3600

ctttcattgt gggagaccag gtgagcatct gccccatgc tgcccttcc tcgcccaccc
3660

ctgcttccag atggacacag gtgtgagcca tttgttagc aaagcagagc agacctagg
3720

gatgggctta ggccctctgc ccccaattcc tccagcctgc tcccgctggc tgagtcccta
3780

gccccctgc cctgcagatc tccttcgtc actacaacct gctggacttg ctgctgatcc
3840

atgaggtcct agcccctggc tgccctggatg cgttccct gctctcagca tatgtggggc
3900

gcctcagtgc ccggcccaag ctcaaggcct tcctggcctc ccctgagtac gtgaacctcc
3960

ccatcaatgg caacggaaa cagtgagggc tggggggact ctgagcggga ggcagagttt
4020

gccttcctt ctccaggacc aataaaattt ctaagagagc tactatgagc actgtgtttc
4080

ctgggacggg gcttaggggt tctcagcctc gaggtcggtg ggagggcaga gcagaggact
4140

agaaaacagc tcctccagca cagtcagtgg cttcctggag ccctcagcct ggctgtgttt
4200

actgaacctc acaaactaga agaggaagaa aaaaaaagag agagagaaac aaagagaaat
4260

a
4261

Fig.

Fig. 1
Reaction of cytosines in nucleic acids with bisulfite




Fig. 2 a)




Fig. 2 b)




Fig. 3 a




Fig. 3 b)




Fig. 4 a)





Fig. 4 b)



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.